1 | Selection of priority NPs for evaluation as potential precipitants of NPDIs | 2, 3, and 7–9 |
2 | Identification and characterization of optimal NP study materials for NPDIs | 1, 3, and 8 |
3 | Evaluation of a potential NPDI using static and dynamic pharmacokinetic modeling of data obtained from in vitro systems and human pharmacokinetic studies | 2–6 |
4 | Design of phase 0 studies to understand NP constituent pharmacokinetics to inform design of a clinical NPDI study | 5–7 and 9 |
5 | Design of clinical NPDI studies using appropriate NP formulation, object drug(s), and human subject group(s) | 3–9 |
6 | Design and creation of a data repository and public portal of the NaPDI Center’s NPDI data for access by researchers | 1–3, 8, and 9 |